KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Deffered Revenue (2016 - 2022)

Pacira BioSciences (PCRX) has 10 years of Non-Current Deffered Revenue data on record, last reported at $10.1 million in Q1 2022.

  • For Q1 2022, Non-Current Deffered Revenue changed N/A year-over-year to $10.1 million; the TTM value through Mar 2022 reached $10.1 million, changed N/A, while the annual FY2021 figure was $10.1 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $10.1 million in Q1 2022 per PCRX's latest filing, roughly flat from $10.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.1 million in Q4 2021 and bottomed at $10.1 million in Q4 2021.